BX Mozart ML-2 Holdco L.P. sold $1.2B of MDLN (indirect holdings)

BX Mozart ML-2 Holdco L.P. sold 33,317,824 indirectly-held shares of Medline Inc. (MDLN) at $36.54 ($1.22B total) across 4 trades on 2026-05-28. Filed jointly with BX Mozart ML-1 Holdco L.P. (10% owner), Mozart Aggregator II UNLV Holdco L.P. (10% owner), Mozart Aggregator UNLV Holdco L.P. (10% owner), Mozart Aggregator II LP (10% owner), BX Mozart ML-2 Holdco GP L.L.C. (10% owner), BX Mozart ML-1 Holdco GP L.L.C. (10% owner), BCP Mozart Aggregator L.P. (10% owner) and Blackstone Management Associates VIII L.P. (10% owner).

Original reporting
SEC EDGAR · BX Mozart ML-2 Holdco L.P., BX Mozart ML-1 Holdco L.P., Mozart Aggregator II UNLV Holdco L.P., Mozart Aggregator UNLV Holdco L.P., Mozart Aggregator II LP, BX Mozart ML-2 Holdco GP L.L.C., BX Mozart ML-1 Holdco GP L.L.C., BCP Mozart Aggregator L.P., Blackstone Management Associates VIII L.P.
Published Jun 1, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDLN
Bearish
high confidence
Mentioned
$MDLN
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDLNBearishMed
01

Why it matters

The disclosure provides fresh, material information that could affect MDLN's short‑term price dynamics.

02

Market read

A $1.2 B insider sale is a primary market‑moving event for MDLN.

03

What to watch

Potential tax‑loss harvesting or pre‑planned liquidity needs may have driven the sale.

Relevance 9/10Novelty 9/10Timing: post‑market today

Background

SEC Form 4 filing by BX Mozart ML‑2 Holdco L.P. reporting a large insider divestiture in Medline Inc.

Company-level read

Ticker impact

$MDLNBearishHigh confidence
Context

Form 4 disclosed a $1.2 B open‑market sale of 33.3 M shares by a 10% owner, reducing holdings to 1,539 shares.

Expected impact

likely pressure as the market prices in the sizable insider sale

Evidence & confidence

The transaction size ($1.2 B) is material for a mid‑cap and signals reduced confidence from a major shareholder.

Market effects

May raise concerns for the medical‑supplies sector about insider confidence.

Limited to U.S. markets where MDLN trades.

Minimal beyond the company's own share price.

Counterpoint

The sale could be a portfolio rebalancing unrelated to company fundamentals, offering a buying opportunity.

Key entities

  • Medline Inc.

    Medical‑supplies manufacturer (ticker MDLN).

  • BX Mozart ML‑2 Holdco L.P.

    10% owner of Medline filing the Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDLNMed

Medline stock falls as shareholders price secondary offering

Medline Inc (MDLN) shares fell 3.5% premarket after selling stockholders, including affiliates of Blackstone and Carlyle, priced a 60M share secondary offering at $35.50 per share. Medline will repurchase $200M of stock from these sellers. The offering is expected to close November 23, 2026, with underwriters having a 30-day option for additional shares. Medline is not selling shares and will not receive proceeds.

$MDLNHighAI 9/10

Why is Medline stock sliding today?

Medline (MDLN) stock fell 3.3% in pre-market trading after a consortium of shareholders priced a secondary offering of 60 million shares at $35.50 each, totaling $2.13 billion. The offering's below-market price and a securities fraud investigation by Bleichmar Fonti & Auld LLP contributed to the decline. Medline is not selling shares and will not receive proceeds. The stock has dropped significantly from its 52-week high of $50.88.